<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016781</url>
  </required_header>
  <id_info>
    <org_study_id>BMTCTN1102</org_study_id>
    <secondary_id>2U10HL069294-11</secondary_id>
    <secondary_id>5U24CA076518</secondary_id>
    <nct_id>NCT02016781</nct_id>
  </id_info>
  <brief_title>Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)</brief_title>
  <official_title>A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 &amp; High Risk Myelodysplastic Syndrome (BMT CTN #1102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood and Marrow Transplant Clinical Trials Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marrow Donor Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multicenter trial, with biological assignment to one of two study
      arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation
      (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: MDS is a clonal disorder of hematopoietic precursors and stem cells, which may
      evolve to a terminal phase resembling acute leukemia. A subject of clinical urgency for
      researchers, clinicians, patients, and health care underwriters such as Medicare, is the role
      of allogeneic hematopoietic cell transplantation (alloHCT) in the treatment of older patients
      with higher risk myelodysplastic syndromes (MDS). The use of reduced intensity conditioning
      (RIC) regimens has extended HCT to the care of older patients with acute myelogenous leukemia
      (AML) and lymphoma and a number of retrospective and phase II trials for patients with MDS
      now show the curative potential of RIC alloHCT in selected patients.

      This protocol is designed to evaluate the relative benefits of RIC alloHCT compared to
      non-transplant therapies focusing on overall survival. This will be done by having patients
      biologically assigned to the alloHCT arm or the hypomethylating therapy/best supportive care
      arm and following them for survival at 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two arms will enroll and have data collected on them simultaneously.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years</time_frame>
    <description>Overall survival is calculated for all patients from date of patient consent until death from any cause. Observation is censored at the date of last follow-up for patients last known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Leukemia-free survival (LFS)</measure>
    <time_frame>3 years</time_frame>
    <description>LFS is defined as the time from the date of patient consent to the date of progression to AML or death from any cause, whichever comes first. Observation is censored at the date of last follow-up for patients known to be alive without leukemia. Progression to AML is defined as &gt; 20% leukemic blasts in bone marrow or in the peripheral blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants on HCT arm with disease relapse</measure>
    <time_frame>3 years</time_frame>
    <description>Disease relapse for patients with MDS is defined as: Satisfying criteria for evolution into acute leukemia; or reappearance of pre-transplant morphologic abnormalities, detected in bone marrow specimens; or reappearance of pre-transplant cytogenetic abnormality in at least one metaphase on each of two separate consecutive examinations at least one month apart, regardless of the number of metaphases analyzed; or institution of any therapy to treat relapsed disease (institution of any therapy not meant for maintenance or prevention), including withdrawal of immunosuppressive therapy or DLI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-Effectiveness Analysis (CEA)</measure>
    <time_frame>3 years</time_frame>
    <description>The primary endpoint for the CEA will be the cost per quality-adjusted life year (QALY) from the third party payer perspective with two time horizons: (1) within trial (at 3 years post-enrollment), and (2) lifetime using simulating modeling.
The secondary endpoint for the CEA is the cost per QALY from the societal perspective, a broader measure that captures health insurer direct medical care costs and patient out-of-pocket direct medical and direct non-medical costs. Patient productivity costs (captured as part of QALY calculations) will be reported separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) - (Functional Assessment of Cancer Therapy-Bone Marrow Transplant) FACT-BMT</measure>
    <time_frame>3 years</time_frame>
    <description>QOL will be compared between the 2 arms using the FACT-BMT survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) - Medical Outcomes Study Short Form (MOS SF-36)</measure>
    <time_frame>3 years</time_frame>
    <description>QOL will be compared between the 2 arms using the MOS SF-36 survey.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) - EQ-5D</measure>
    <time_frame>3 years</time_frame>
    <description>QOL will be compared between the 2 arms using the EQ-5D survey.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">384</enrollment>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>Transplant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypomethylating Therapy / Best Supportive Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The specific non-transplant treatment regimen will be at the discretion of the treating physician.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Cell Transplant</intervention_name>
    <description>Bone marrow or peripheral blood stem cell transplant.from a fully matched related (6/6) or unrelated (8/8) donor. The specific transplant treatment regimen will be at the discretion of the treating physician but is required to be reduced-intensity.</description>
    <arm_group_label>Transplant</arm_group_label>
    <other_name>RIC alloHCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hypomethylating Therapy / Best Supportive Care</intervention_name>
    <description>The specific non-transplant treatment regimen will be at the discretion of the treating physician.</description>
    <arm_group_label>Hypomethylating Therapy / Best Supportive Care</arm_group_label>
    <other_name>Non-transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients fulfilling the following criteria will be eligible for entry into this study:

               1. Patients with de novo MDS who have, or have previously had, Intermediate-2 or
                  High risk disease as determined by the International Prognostic Scoring System
                  (IPSS). Current Intermediate-2 or High risk disease is NOT a requirement.

               2. Patients must have an acceptable MDS subtype:

                    -  Refractory cytopenia with unilineage dysplasia (RCUD) (includes refractory
                       anemia (RA))

                    -  Refractory anemia with ringed sideroblasts (RARS)

                    -  Refractory anemia with excess blasts (RAEB-1)

                    -  Refractory anemia with excess blasts (RAEB-2)

                    -  Refractory cytopenia with multilineage dysplasia (RCMD)

                    -  Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)

                    -  Myelodysplastic syndrome (MDS), unclassifiable

               3. Patients must have fewer than 20% marrow blasts within 60 days of consent.

               4. Patients may have received prior therapy for the treatment of MDS, including but
                  not limited to: growth factor, transfusion support, immunomodulatory (IMID)
                  therapy, DNA hypomethylating therapy, or cytotoxic chemotherapy prior to
                  enrollment.

               5. Age 50.0-75.0 years.

               6. Karnofsky performance status &gt; 70 or Eastern Cooperative Oncology Group (ECOG) â‰¤
                  1.

               7. Patients are eligible if no formal unrelated donor search has been activated
                  prior to date of consent. A formal unrelated donor search begins at the time at
                  which samples are requested from potential National Marrow Donor Program (NMDP)
                  donors. Patients who have started a sibling donor search or who have found a
                  matched sibling donor are eligible.

               8. Patients and physicians must be willing to comply with treatment assignment:

                    1. No intent to proceed with alloHCT using donor sources not specified in this
                       protocol, including human leukocyte antigen (HLA)-mismatched related or
                       unrelated donors (&lt; 6/6 HLA related matched or &lt; 8/8 HLA unrelated matched)
                       or umbilical cord blood unit(s).

                    2. No intent to use myeloablative conditioning regimens.

                    3. Intent to proceed with RIC alloHCT if a matched sibling or matched unrelated
                       donor is identified. There is no requirement as to the timing of the
                       transplantation.

               9. Patients must be considered to be suitable RIC alloHCT candidates at the time of
                  enrollment based on medical history, physical examination, and available
                  laboratory tests. Specific testing for organ function is not required for
                  eligibility but, if available, these tests should be used to judge eligibility.

              10. Signed informed consent

        Exclusion Criteria:

          -  Patients with the following will be ineligible for registration onto this study:

               1. Therapy-related MDS (defined as the occurrence of MDS due to prior exposure to
                  systemic chemotherapy and/or radiation for malignancy)

               2. Current or prior diagnosis of AML

               3. Chronic myelomonocytic leukemia or myelodysplastic/myeloproliferative neoplasm
                  (unacceptable MDS subtypes); uncontrolled bacterial, viral or fungal infection
                  (currently taking medication and with progression or no clinical improvement) at
                  time of enrollment.

               4. Patients with prior malignancies, except treated non-melanoma skin cancer or
                  treated cervical carcinoma in situ. Cancer treated with curative surgery without
                  chemotherapy/radiation therapy &gt; 5 years previously will be allowed. Cancer
                  treated with curative surgery &lt; 5 years previously will not be allowed unless
                  approved by the Protocol Officer or one of the Protocol Chairs.

               5. Prior autologous or allogeneic HCT

               6. Human Immunodeficiency Virus (HIV) infection

               7. Patients of childbearing potential unwilling to use contraceptive techniques

               8. Patients with psychosocial conditions that would prevent study compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Horowitz, MD, MS</last_name>
    <role>Study Director</role>
    <affiliation>Center for International Blood and Marrow Transplant Research (CIBMTR), Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida College of Medicine</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Systems - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Brigham &amp; Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute/BMT</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University/Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospital at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital BMT Program</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland/ Case Western</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State/Arthur G. James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine/The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson CRC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Med School</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University MCV Hospitals</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia University Hospital</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bmtctn.net/</url>
    <description>Blood and Marrow Transplant Clinical Trials Network Website</description>
  </link>
  <link>
    <url>http://bethematch.org</url>
    <description>National Marrow Donor Program</description>
  </link>
  <reference>
    <citation>Saber W, Le Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum FR, Horowitz MM, Nakamura R, Cutler CS. Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. Biol Blood Marrow Transplant. 2014 Oct;20(10):1566-72. doi: 10.1016/j.bbmt.2014.06.010. Epub 2014 Jun 24.</citation>
    <PMID>24972249</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 16, 2013</study_first_submitted>
  <study_first_submitted_qc>December 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Within 6 months of official study closure at participating sites.</ipd_time_frame>
    <ipd_access_criteria>Available to the public</ipd_access_criteria>
    <ipd_url>https://biolincc.nhlbi.nih.gov/home/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

